Clinical Trial on Safety, Immunogenicity, and Efficacy of a Prime Boost Regimen of DNA- and Adenovirus-vectored Malaria Vaccines Encoding Plasmodium Falciparum Circumsporozoite Protein and Apical Membrane Antigen 1 in Malaria-Naïve Adults in the US.

Trial Profile

Clinical Trial on Safety, Immunogenicity, and Efficacy of a Prime Boost Regimen of DNA- and Adenovirus-vectored Malaria Vaccines Encoding Plasmodium Falciparum Circumsporozoite Protein and Apical Membrane Antigen 1 in Malaria-Naïve Adults in the US.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 May 2017

At a glance

  • Drugs Malaria vaccine (Primary) ; Malaria DNA vaccine
  • Indications Falciparum malaria
  • Focus Adverse reactions
  • Acronyms DNA-Ad
  • Most Recent Events

    • 02 May 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
    • 02 May 2017 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
    • 28 Dec 2015 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top